PL367478A1 - Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors - Google Patents

Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors

Info

Publication number
PL367478A1
PL367478A1 PL02367478A PL36747802A PL367478A1 PL 367478 A1 PL367478 A1 PL 367478A1 PL 02367478 A PL02367478 A PL 02367478A PL 36747802 A PL36747802 A PL 36747802A PL 367478 A1 PL367478 A1 PL 367478A1
Authority
PL
Poland
Prior art keywords
furan
peroxisome proliferator
activated receptors
proliferator activated
thiophene derivatives
Prior art date
Application number
PL02367478A
Other languages
English (en)
Polish (pl)
Inventor
Paul John Beswick
Christopher Charles Frederick Hamlett
Vipulkumar Patel
Michael Lawrence Sierra
Nigel Grahame Ramsden
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL367478A1 publication Critical patent/PL367478A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
PL02367478A 2001-05-11 2002-05-09 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors PL367478A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111523.7A GB0111523D0 (en) 2001-05-11 2001-05-11 Chemical compounds

Publications (1)

Publication Number Publication Date
PL367478A1 true PL367478A1 (en) 2005-02-21

Family

ID=9914442

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02367478A PL367478A1 (en) 2001-05-11 2002-05-09 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors

Country Status (20)

Country Link
US (1) US7091237B2 (enExample)
EP (1) EP1392674B1 (enExample)
JP (1) JP2004534035A (enExample)
KR (1) KR20040023600A (enExample)
CN (1) CN1507442A (enExample)
AT (1) ATE301649T1 (enExample)
BR (1) BR0209468A (enExample)
CA (1) CA2446797A1 (enExample)
CO (1) CO5540343A2 (enExample)
CZ (1) CZ20033064A3 (enExample)
DE (1) DE60205481T2 (enExample)
ES (1) ES2247322T3 (enExample)
GB (1) GB0111523D0 (enExample)
HU (1) HUP0304051A3 (enExample)
IL (1) IL158332A0 (enExample)
MX (1) MXPA03010285A (enExample)
NO (1) NO20034986D0 (enExample)
PL (1) PL367478A1 (enExample)
WO (1) WO2002092590A1 (enExample)
ZA (1) ZA200308352B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
WO2003016291A1 (en) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
JP2005035966A (ja) * 2002-09-06 2005-02-10 Takeda Chem Ind Ltd フランまたはチオフェン誘導体およびその医薬用途
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7504433B2 (en) * 2003-01-06 2009-03-17 Eli Lilly And Company Thiophene derivative PPAR modulators
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MX2007010511A (es) * 2005-02-28 2007-11-07 Nippon Chemiphar Co Activador para el receptor ( activador del proliferador peroxisoma.
US7982050B2 (en) 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
RU2007148439A (ru) * 2005-05-25 2009-06-27 Ниппон Кемифар Ко., Лтд. (JP) Активатор для рецептора, активируемого пролифератором пероксисом
BRPI0616465A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US20090012133A1 (en) * 2006-01-10 2009-01-08 Smithkline Beecham Corporation Polymorphic Form of -Acetic Acid
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
FR2910894A1 (fr) * 2006-12-29 2008-07-04 Genfit Sa Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation.
EP2114396A4 (en) 2006-12-29 2010-03-10 Salk Inst For Biological Studi METHOD FOR IMPROVING TRAINING PERFORMANCE
JP2010519308A (ja) * 2007-02-23 2010-06-03 イーライ リリー アンド カンパニー ペルオキシソーム増殖剤活性化受容体修飾因子
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
DE102008007400A1 (de) * 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
WO2014159054A1 (en) * 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
NZ710855A (en) * 2013-03-14 2020-03-27 Dow Agrosciences Llc Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3212825A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands

Also Published As

Publication number Publication date
US20040157890A1 (en) 2004-08-12
KR20040023600A (ko) 2004-03-18
JP2004534035A (ja) 2004-11-11
DE60205481T2 (de) 2006-05-24
BR0209468A (pt) 2004-08-03
HUP0304051A2 (hu) 2004-04-28
ES2247322T3 (es) 2006-03-01
ATE301649T1 (de) 2005-08-15
CA2446797A1 (en) 2002-11-21
CO5540343A2 (es) 2005-07-29
IL158332A0 (en) 2004-05-12
WO2002092590A1 (en) 2002-11-21
ZA200308352B (en) 2005-01-27
EP1392674B1 (en) 2005-08-10
CZ20033064A3 (cs) 2004-02-18
NO20034986L (no) 2003-11-10
GB0111523D0 (en) 2001-07-04
NO20034986D0 (no) 2003-11-10
US7091237B2 (en) 2006-08-15
EP1392674A1 (en) 2004-03-03
CN1507442A (zh) 2004-06-23
MXPA03010285A (es) 2004-03-09
DE60205481D1 (de) 2005-09-15
HUP0304051A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
IL158332A0 (en) Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
DK1452524T3 (da) "2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser"
TW200716572A (en) Peroxisome proliferator activated receptor alpha agonists
CA2377126A1 (en) Thiazole and oxazole derivatives and their pharmaceutical use
MY138352A (en) Benzothiazole derivatives
NZ514574A (en) Novel method of treatment
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
IL159002A0 (en) Modulators of peroxisome proliferator activated receptors (ppar)
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
PL375964A1 (en) Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
AP2004003124A0 (en) Thiazole and oxazole derivatives which modulate PPAR activity
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
HK1049618A1 (zh) 骨質形成調節
WO2005077926A3 (en) Benzofuran and benzothiophene derivatives useful for the treatment of cardiovascular disease
PL367291A1 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
EP1537875A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF ARTERIOSCLEROSIS
YU67402A (sh) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
DE60026559D1 (de) Arzneimittel gegen essstörungen
HK1063634A (en) Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
SE9802119D0 (sv) New use
SE9900438D0 (sv) The pharmacological use of certian cystine derivatives
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
SI1148881T1 (sl) Uporaba derivatov pridazino - (4,5-(b))-indol-1-acetamida za pripravo zdravil za bolezni, povezane z disfunkcijo perifernih benzodiazepinskih receptorjev

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)